ISRG · Q3 2024 Earnings

Bullish

Intuitive Surgical

Reported October 21, 2025

30-second summary

Intuitive printed Q3 revenue of $2.51B (+23% YoY) on da Vinci procedure growth of 19% and 427 system placements, of which 240 were da Vinci 5 — the DV5 share of placements stepped up to ~56% from 46% in Q2. More important than the print: FY2025 procedure growth guidance was raised from 15.5–17% to 17–17.5%, non-GAAP gross-margin guidance was raised from 66–67% to 67–67.5%, and the tariff drag estimate was cut from ~1.0% of revenue to ~0.7% with the uncertainty band halved. The setup that looked margin-pressured at Q2 has materially de-risked on tariffs, mix, and underlying procedure demand.

Headline numbers

EPS

Q3 FY2024

$2.40

Revenue

Q3 FY2024

$2.51B

+23.0% YoY

Gross margin

Q3 FY2024

66.3%

Operating margin

Q3 FY2024

30.3%

Key financials

Q3 FY2024

Metric	Q3 FY2024	YoY	Q2 FY2025	QoQ
Revenue	$2.51B	+23.0%	$2.44B	+2.9%
EPS	$2.40	—	$2.19	+9.6%
Gross margin	66.3%	—	66.3%	+0bps
Operating margin	30.3%	—	30.5%	-20bps

Guidance

Intuitively Surgical raised full-year FY2025 da Vinci procedure growth guidance and non-GAAP gross margin guidance while narrowing tariff impact estimate, signaling operational momentum and improved margin resilience despite prior concerns.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Da Vinci procedure growth	Q3 FY2024	Not explicitly provided in prior quarter next_quarter block	19%	+2 percentage points above FY2024 baseline (17%)	Beat

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Da Vinci procedure growth	FY 2025	approximately 15.5% to 17%	approximately 17% to 17.5%	+1.5 to +2 percentage points at midpoint	Raised
Non-GAAP gross profit margin	FY 2025	66% to 67% of revenue	67% to 67.5% of revenue	+100 to +150 basis points	Raised
Non-GAAP operating expense growth	FY 2025	10% to 14%	11% to 13%	-100 to -300 basis points; range narrowed	Lowered
Tariff impact on gross margin	FY 2025	1.0% of revenue, plus or minus 20 basis points	0.7% of revenue, plus or minus 10 basis points	-30 basis points at midpoint; uncertainty range halved	Lowered

Segment KPIs

Q3 FY2024

Segment	Q3 FY2024	YoY
Instruments and Accessories	$1.519B	+20.0%
Systems	$0.59B	+32.6%
Services	$0.396B	+20.4%

Other KPIs

Q3 FY2024

Segment	Q3 FY2024
da Vinci Procedure Growth (YoY)	19%
Ion Procedure Growth (YoY)	52%
da Vinci Surgical System Placements	427 units
da Vinci 5 System Placements	240 units
Ion Endoluminal System Placements	50 units
da Vinci Installed Base	10,763 systems
Ion Installed Base	954 systems
Non-GAAP Operating Margin	38.9%

Management tone

Q2 anchor: "Q2 op margin is not the new normal" → Q3 anchor: FY guide raised on both procedure growth and margin.

The Q2 call was dominated by management actively talking down the operating margin print, citing a favorable purchase-lease mix and 9% OPEX growth as non-recurring tailwinds. The Q3 release does the opposite work: the FY2025 non-GAAP gross-margin guide was raised 100bps at the midpoint while the tariff line item is still 0.7% of revenue, and OPEX growth was narrowed with the upper bound cut. The 38.9% Q3 operating margin landed essentially in line with the 38.8% Q2 print management had explicitly cautioned investors not to extrapolate. That is a posture change — from underpromise to confirmed operating leverage.

The tariff narrative has shifted from open-ended risk to quantified, narrowing exposure. At Q2 the FY tariff drag was framed as ~1.0% of revenue ±20bps with "additional impact could be material" language; this quarter it is ~0.7% ±10bps. Midpoint cut by 30bps, uncertainty band halved. Whether that reflects mitigation, policy delay, or a combination, management has chosen to communicate higher confidence — and is willing to raise gross margin against it.

One organizational note worth flagging: CFO Brian King departed ("moved on to pursue his next opportunity"), with a search underway. The prepared remarks were unusually brief and led with this announcement rather than operating commentary — atypical for a quarter where guidance was raised on multiple lines. The transition does not yet appear to be affecting the guide architecture, but a CFO vacancy during a margin-expansion narrative is execution risk to monitor.

Recurring themes management leaned on this quarter:

Business continuity during leadership transitionStandard forward-looking statement disclaimersQ3 2024 results review

Risks management surfaced:

Risks and uncertainties described in SEC filingsMaterial differences between actual and expressed/implied results possible

Q&A highlights

Travis Steed · Bank of America

Inquired about DaVinci 5 ramp trajectory to mid-2025 broad launch, expected software upgrades, and hospital CFO receptiveness to contribution margin benefits and profitability data from DaVinci 5.

Management confirmed continued semi-routine software updates with a scheduled release enabling hardware and additional features at broad launch. Supply expected to increase modestly quarter over quarter. Early KOL surgeons reporting console time savings; early feedback focused on efficiency gains driving higher throughput and contribution margin improvements, though validated evidence collection ongoing through broad launch.

Semi-routine software updates continuing to broad launchSupply to increase modestly quarter over quarter into broad launchEarly surgeons reporting improvements in console time and procedure efficiencyEarly publication illustrated potential contribution margin gains from efficiency improvements

Larry Beagleson · Wells Fargo

Asked about supply readiness for Korea launch, Japan regulatory timing, Europe CE mark timeline, and commercial status of emerging procedures (appendectomy, foregut, hepatobiliary).

Korea launch has supply support ready. Japan timing remains uncertain (back and forth in regulatory process). Europe CE mark expected near end of 2025. Foregut and hepatobiliary procedures have been in U.S. market for time with accretive growth rates but small categories. Appendectomy is earlier stage, small procedure, concentrated in emergent settings, with FDA indication already obtained.

Korea DaVinci 5 clearance received with supply availableJapan regulatory timeline uncertain; ongoing back and forthEurope CE mark expected near end of 2025Foregut and HPB growing at accretive rates but remain small categories

Robbie Marcus · JP Morgan

Asked about gross margin and operating margin expansion opportunity given DaVinci 5 flow-through, new facility depreciation, and strategy for refurbished XI trade-in inventory repurposing.

Management targets top-tier MedTech margins without objective to exceed 40%. Expects 2025 gross margins lower due to significant incremental depreciation from new facilities. Mid-term aspiration to return to 70% gross margin. Refurbished XIs from trade-in cycle will enable site-of-care and international market segmentation, with plans to be developed. No specific objective above 40% operating margin.

2024 year-to-date operating margin 36%No management objective to exceed 40% operating margin2025 gross margins expected lower due to incremental depreciation from new facilitiesMid-term gross margin aspiration of 70%

David Roman · Goldman Sachs

Asked about ION adoption trajectory by geography (U.S., Europe, China), trajectory of usage-based arrangement penetration (up from 12% to 15%), and implications for P&L.

ION in U.S. has crossed the chasm with double-digit prevalence in biopsy use; focus now on high utilization and additional indications. Europe and China are early-stage launches. Usage-based arrangements are subset of operating leases, slightly accretive to purchase due to embedded interest; popular with customers but highly penetrated in U.S. with moderate growth expected; international markets much earlier stage.

ION U.S. in double-digit prevalence of total biopsy use; crossed the chasmION Europe and China at very early launch stagesUsage-based arrangements increased from 12% to 15% of placementsUsage-based arrangements slightly accretive to purchase due to embedded interest rates

Rick Wise · Stifel

Asked whether larger academic hospitals are delaying DaVinci 5 purchases waiting for dual console availability while mid-size/smaller hospitals adopt faster, and whether dual console availability at broad launch will accelerate multi-system placement decisions.

Single consoles prioritized in DaVinci 5 ramp; dual consoles will be produced as capacity builds. Management does not expect significant procedure growth model changes from dual console availability or hospital size differences. Broad launch will serve all customer segments without material inflection in procedure growth. Hub adoption strong at 2,000 ORs; currently strong data recorder and media management device with early cloud implementations; plans to refine workflow and integrate with DaVinci 5.

Single consoles prioritized during DaVinci 5 ramp supply phaseDual consoles to be prioritized as production capacity increasesNo expected significant forecast model change from dual console timing or hospital size segmentationProcedure growth expected without material inflection from dual console availability

Answers to last quarter's watch list

Non-GAAP gross margin trajectory toward the 66–67% FY band — The FY non-GAAP gross-margin guide was raised to 67–67.5%, not pressured into the lower band. GAAP gross margin held at 66.3% sequentially despite DV5 mix expansion. Tariff drag cut to 0.7% of revenue from 1.0%. Status: Resolved positively

da Vinci 5 share of systems placed — DV5 share stepped up to 240 of 427 (~56%), from ~46% in Q2. Europe CE mark guided to near end of 2025, Japan still uncertain, Korea cleared with supply available. The U.S. broad-launch absorption is happening; international contribution is still ahead. Status: Resolved positively

Trade-in count — The company did not disclose a Q3 trade-in count in the press-release-only data set; Q&A flagged refurbished XIs as a future segmentation lever rather than quantifying current trade-in volume. Status: Continue monitoring

Procedure growth at the upper end vs. lower end of 15.5–17% FY guide — Q3 came in at +19% and the FY guide was raised to 17–17.5%. The prior range was not front-loaded; the run-rate is above it. Status: Resolved positively

INA per procedure direction — Not explicitly quantified in the disclosed materials this quarter. I&A revenue grew 20% YoY against 19% procedure growth, suggesting INA per procedure is roughly flat to modestly positive, but the company didn't break it out. Status: Continue monitoring

International system placements, specifically Japan — Japan was not quantified in the available data; management noted Japan DV5 regulatory timing remains uncertain. No confirmation the Japan placement trough is in. Status: Continue monitoring

What to watch into next quarter

Whether FY2025 procedure growth lands at or above the new 17–17.5% guide top end — Q3 ran +19% YoY; a Q4 print below 17% would suggest the raised guide is being met by tougher comps rather than sustained acceleration.

DV5 share of placements above 60% — DV5 hit ~56% in Q3 (240 of 427); continued sequential expansion validates the broad-launch absorption thesis. A stall in the mid-50s would be the first sign of a saturation point in U.S. demand.

Non-GAAP gross margin landing inside or above the new 67–67.5% FY band — the guide was raised, but new-facility depreciation and tariff exposure remain. Watch for the implied Q4 print and the FY2026 framing on the next call.

CFO replacement and continuity of guidance architecture — Brian King's departure is mid-cycle; watch whether the new CFO maintains the FY-only guide structure and the tariff disclosure granularity, or recalibrates the framework.

Tariff line at 0.7% ±10bps holding through Q4 — a re-widening of the uncertainty band or a midpoint walk-up would signal the de-risking was premature.

Europe CE mark for DV5 by end of 2025 and Japan regulatory clarity — both are now near-term catalysts management has committed to publicly; slippage on either would mark the first guidance credibility test for the new posture.

Sources

Intuitive Surgical Q3 2025 earnings press release, filed with SEC (https://www.sec.gov/Archives/edgar/data/1035267/000103526725000206/q325ex-991earningsrelease.htm)
Intuitive Surgical Q3 2025 earnings call Q&A (analyst exchanges with Bank of America, Wells Fargo, JP Morgan, Goldman Sachs, Stifel)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.